Focus of the Report: This report evaluates the analytical validity, clinical validity, and clinical utility of the Food and Drug Administration–approved Epi proColon blood-based liquid biopsy test, for the detection of methylated Septin 9 (SEPT9) as cell-free circulating DNA, that is intended to screen for colorectal cancer (CRC) in average-risk adult patients (≥ 50 years of age) who have been offered and have a history of not completing CRC screening.
If you have a Hayes login, click here to view the full report on the Knowledge Center.